Fjarde AP Fonden Fourth Swedish National Pension Fund Boosts Stock Holdings in IDEXX Laboratories, Inc. $IDXX

Fjarde AP Fonden Fourth Swedish National Pension Fund lifted its position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 72.8% in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 41,412 shares of the company’s stock after acquiring an additional 17,440 shares during the period. Fjarde AP Fonden Fourth Swedish National Pension Fund owned approximately 0.05% of IDEXX Laboratories worth $23,269,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds also recently added to or reduced their stakes in IDXX. Virtus Advisers LLC purchased a new stake in shares of IDEXX Laboratories during the third quarter valued at $26,000. SHP Wealth Management purchased a new position in IDEXX Laboratories in the 4th quarter worth about $26,000. Park Place Capital Corp purchased a new position in IDEXX Laboratories in the 4th quarter worth about $29,000. WealthCollab LLC bought a new position in IDEXX Laboratories during the 2nd quarter valued at about $30,000. Finally, Caitong International Asset Management Co. Ltd bought a new position in IDEXX Laboratories during the 3rd quarter valued at about $36,000. 87.84% of the stock is currently owned by hedge funds and other institutional investors.

IDEXX Laboratories Stock Performance

IDEXX Laboratories stock opened at $557.80 on Friday. IDEXX Laboratories, Inc. has a 52-week low of $506.91 and a 52-week high of $769.98. The company has a market cap of $44.00 billion, a P/E ratio of 41.08, a P/E/G ratio of 3.05 and a beta of 1.55. The company has a quick ratio of 0.82, a current ratio of 1.12 and a debt-to-equity ratio of 0.19. The business has a 50-day simple moving average of $555.31 and a two-hundred day simple moving average of $609.16.

IDEXX Laboratories (NASDAQ:IDXX) last issued its quarterly earnings data on Tuesday, May 5th. The company reported $3.47 earnings per share for the quarter, topping the consensus estimate of $3.41 by $0.06. The firm had revenue of $1.14 billion for the quarter, compared to analysts’ expectations of $1.12 billion. IDEXX Laboratories had a net margin of 24.63% and a return on equity of 70.87%. The business’s quarterly revenue was up 14.3% on a year-over-year basis. During the same quarter in the prior year, the business earned $2.91 EPS. IDEXX Laboratories has set its FY 2026 guidance at 14.450-14.900 EPS. Analysts predict that IDEXX Laboratories, Inc. will post 14.68 EPS for the current year.

Analysts Set New Price Targets

A number of analysts have recently commented on IDXX shares. UBS Group reduced their price target on shares of IDEXX Laboratories from $730.00 to $640.00 and set a “neutral” rating for the company in a research note on Tuesday, April 28th. Citigroup assumed coverage on shares of IDEXX Laboratories in a research report on Wednesday, April 15th. They set a “neutral” rating and a $650.00 price objective on the stock. Weiss Ratings upgraded shares of IDEXX Laboratories from a “hold (c)” rating to a “hold (c+)” rating in a report on Thursday, June 25th. Wall Street Zen raised shares of IDEXX Laboratories from a “hold” rating to a “buy” rating in a research report on Saturday, June 13th. Finally, Stifel Nicolaus decreased their target price on shares of IDEXX Laboratories from $775.00 to $675.00 and set a “buy” rating for the company in a research note on Tuesday, March 31st. Seven investment analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $751.00.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.